Free Trial

Verrica Pharmaceuticals (VRCA) Competitors

Verrica Pharmaceuticals logo
$0.70 -0.02 (-2.38%)
Closing price 07/23/2025 04:00 PM Eastern
Extended Trading
$0.70 -0.01 (-1.25%)
As of 06:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VRCA vs. ALDX, VOR, CRVS, SGMT, DBVT, ANNX, AVTE, ALLO, TVRD, and ZYBT

Should you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Aldeyra Therapeutics (ALDX), Vor Biopharma (VOR), Corvus Pharmaceuticals (CRVS), Sagimet Biosciences (SGMT), DBV Technologies (DBVT), Annexon (ANNX), Aerovate Therapeutics (AVTE), Allogene Therapeutics (ALLO), Tvardi Therapeutics (TVRD), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry.

Verrica Pharmaceuticals vs. Its Competitors

Aldeyra Therapeutics (NASDAQ:ALDX) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

In the previous week, Aldeyra Therapeutics had 2 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 2 mentions for Aldeyra Therapeutics and 0 mentions for Verrica Pharmaceuticals. Aldeyra Therapeutics' average media sentiment score of 0.39 beat Verrica Pharmaceuticals' score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Aldeyra Therapeutics Neutral
Verrica Pharmaceuticals Neutral

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 9.6% of Aldeyra Therapeutics shares are held by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aldeyra Therapeutics has higher earnings, but lower revenue than Verrica Pharmaceuticals. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aldeyra TherapeuticsN/AN/A-$55.85M-$0.97-5.70
Verrica Pharmaceuticals$7.57M8.61-$76.58M-$1.20-0.59

Aldeyra Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500.

Aldeyra Therapeutics presently has a consensus target price of $9.50, indicating a potential upside of 71.79%. Verrica Pharmaceuticals has a consensus target price of $8.00, indicating a potential upside of 1,035.07%. Given Verrica Pharmaceuticals' higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Aldeyra Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aldeyra Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Verrica Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20

Verrica Pharmaceuticals' return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aldeyra TherapeuticsN/A -72.58% -52.32%
Verrica Pharmaceuticals N/A N/A -145.63%

Summary

Aldeyra Therapeutics beats Verrica Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Verrica Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRCA vs. The Competition

MetricVerrica PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$66.78M$2.43B$5.57B$9.42B
Dividend YieldN/A1.80%4.05%3.99%
P/E Ratio-0.599.1428.1520.08
Price / Sales8.61540.89401.6884.07
Price / CashN/A166.9336.1958.45
Price / Book-6.415.168.625.83
Net Income-$76.58M$30.99M$3.24B$258.27M
7 Day Performance-17.59%3.81%3.55%2.69%
1 Month Performance17.86%12.26%11.01%12.91%
1 Year Performance-90.09%0.95%35.56%21.81%

Verrica Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRCA
Verrica Pharmaceuticals
4.2026 of 5 stars
$0.70
-2.4%
$8.00
+1,035.1%
-90.6%$66.78M$7.57M-0.5940
ALDX
Aldeyra Therapeutics
2.3757 of 5 stars
$5.01
+7.7%
$9.50
+89.6%
+37.9%$300.08MN/A-5.1610Upcoming Earnings
VOR
Vor Biopharma
3.9457 of 5 stars
$2.39
-4.4%
$5.63
+135.5%
+120.0%$298.65MN/A-1.45140High Trading Volume
CRVS
Corvus Pharmaceuticals
1.9477 of 5 stars
$4.35
+5.1%
$15.00
+244.8%
+109.4%$296.54MN/A-4.4430
SGMT
Sagimet Biosciences
2.1699 of 5 stars
$9.46
-0.1%
$26.60
+181.2%
+193.3%$290.14M$2M-5.388News Coverage
Insider Trade
DBVT
DBV Technologies
3.9156 of 5 stars
$10.58
-2.1%
$14.75
+39.5%
+96.7%$289.68M$4.15M-2.1580Upcoming Earnings
Gap Up
ANNX
Annexon
2.3393 of 5 stars
$2.61
+1.2%
$12.50
+378.9%
-57.8%$286.34MN/A-2.2160Negative News
AVTE
Aerovate Therapeutics
N/A$9.82
-6.7%
N/A-85.7%$284.63MN/A-3.2820High Trading Volume
ALLO
Allogene Therapeutics
3.4226 of 5 stars
$1.29
+0.8%
$8.44
+554.6%
-46.1%$282.16M$20K-1.05310
TVRD
Tvardi Therapeutics
N/A$29.83
+9.1%
$64.25
+115.4%
N/A$279.21M$7.14M0.0080Gap Up
High Trading Volume
ZYBT
Zhengye Biotechnology
N/A$5.87
-0.3%
N/AN/A$276.86M$186.36M0.00278Positive News

Related Companies and Tools


This page (NASDAQ:VRCA) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners